Clinical Development of VEGF Signaling Pathway Inhibitors in Childhood Solid Tumors

Learning Objectives After completing this course, the reader will be able to: Identify the mechanism, specificity, relative potency, dosing schedule, important pharmacokinetic characteristics, and agent‐specific side effects of the VEGF signaling pathway inhibitors currently in pediatric development. Describe the different concerns between children and adults regarding the common class side effects of the VEGF pathway inhibitors.This article is available for continuing medical education credit at CME.TheOncologist.com Angiogenesis is a target shared by both adult epithelial cancers and the mesenchymal or embryonal tumors of childhood. Development of antiangiogenic agents for the pediatric population has been complicated by largely theoretical concern for toxicities specific to the growing child and prioritization among the many antiangiogenic agents being developed for adults. This review summarizes the mechanism of action and preclinical data relevant to childhood cancers and early‐phase clinical trials in childhood solid tumors. Single‐agent adverse event profiles in adults and children are reviewed with emphasis on cardiovascular, bone health, and endocrine side effects. In addition, pharmacological factors that may be relevant for prioritizing clinical trials of these agents in children are reviewed. Considerations for further clinical evaluation should include preclinical data, relative potency, efficacy in adults, and the current U.S. Food and Drug Administration approval status. Toxicity profiles of vascular endothelial growth factor (VEGF) signaling pathway inhibitors may be age dependent and ultimately, their utility in the treatment of childhood cancer will require combination with standard cytotoxic drugs or other molecularly targeted agents. In combination studies, toxicity profiles, potential drug interactions, and late effects must be considered. Studies to assess the long‐term impact of VEGF signaling pathway inhibitors on cardiovascular, endocrine, and bone health in children with cancer are imperative if these agents are to be administered to growing children and adolescents with newly diagnosed cancers.